Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Стратегии комбинированной терапии с блокадой PD-1/PD-L1: современные достижения и перспективы
2022-01-21
SCID: 54.1/tnde4t6p
Discuss with AI
PD-1/PD-L1 blockadebispecific/bifunctional antibodiescombination therapyfecal microbiota transplantationtumor microenvironment
Figures from the paper
Abstract (AI)
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for various types of cancers. Nevertheless, the low response rate of α-PD-1/PD-L1 therapy remains to be resolved. For most cancer patients, PD-1/PD-L1 pathway is not the sole speed-limiting factor of antitumor immunity, and it is insufficient to motivate effective antitumor immune response by blocking PD-1/PD-L1 axis. It has been validated that some combination therapies, including α-PD-1/PD-L1 plus chemotherapy, radiotherapy, angiogenesis inhibitors, targeted therapy, other immune checkpoint inhibitors, agonists of the co-stimulatory molecule, stimulator of interferon genes agonists, fecal microbiota transplantation, epigenetic modulators, or metabolic modulators, have superior antitumor efficacies and higher response rates. Moreover, bifunctional or bispecific antibodies containing α-PD-1/PD-L1 moiety also elicited more potent antitumor activity. These combination strategies simultaneously boost multiple processes in cancer-immunity cycle, remove immunosuppressive brakes, and orchestrate an immunosupportive tumor microenvironment. In this review, we summarized the synergistic antitumor efficacies and mechanisms of α-PD-1/PD-L1 in combination with other therapies. Moreover, we focused on the advances of α-PD-1/PD-L1-based immunomodulatory strategies in clinical studies. Given the heterogeneity across patients and cancer types, individualized combination selection could improve the effects of α-PD-1/PD-L1-based immunomodulatory strategies and relieve treatment resistance.
Key Findings
1
Bifunctional or bispecific antibodies containing PD-1/PD-L1 moieties elicit more potent antitumor activity than single-agent PD-1/PD-L1 inhibitors.
2
Blocking PD-1/PD-L1 rescues exhausted T cells and revives antitumor immune responses, but monotherapy yields low response rates for many cancers.
3
Combination therapies (with chemotherapy, radiotherapy, angiogenesis inhibitors, targeted therapy, other checkpoint inhibitors, costimulatory agonists, STING agonists, FMT, epigenetic or metabolic modulators) show superior antitumor efficacy and higher response rates than PD-1/PD-L1 monotherapy.
4
Personalized selection of PD-1/PD-L1-based combination strategies is needed to address patient and tumor heterogeneity and relieve treatment resistance.
5
Ten anti-PD-1 and three anti-PD-L1 antibodies have been clinically approved for various cancers.
Research Object
PD-1/PD-L1 blockade therapies (α-PD-1 and α-PD-L1 antibodies and related bifunctional/bispecific agents) used in cancer treatment
Research Subject
Combination strategies pairing PD-1/PD-L1 blockade with other therapies and the resulting synergistic antitumor efficacies, mechanisms of action, response rates, tumor microenvironment modulation, and clinical advances including individualized selection to overcome resistance
Publication Details
Publication Date
2022-01-21
Journal
Publisher
ISSN
Cited by
1468
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest